Zealand's obesity drug shouldn't disrupt Novo Nordisk-Eli Lilly leadership: Mizuho's
0
0
26/02/24
Dans
Amérique du Nord / États-Unis
Jared Holz, Mizuho, joins 'Fast Money' to talk obesity drugmakers after a new study out of Zealand Pharma analyzed the impact of GLP-1s on liver disease.
Montre plus
0 commentaires
sort Trier par
